Updated:
Break Off Capital
Break Off Capital is an investment firm focused on supporting scientific research addressing global challenges. They have made 17 investments, including a...
Break Off Capital
Break Off Capital is an investment firm focused on supporting scientific research addressing global challenges. They have made 17 investments, including a November 04, 2024, investment in Synthesis Health as part of their Unattributed VC - II.
General information
Firm type
Private Equity
Year founded
2015
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Frequently asked questions
Who runs investment decisions at Break Off Capital?
Break Off Capital does not name any principals, managing partners, or investment committee members in public materials. No regulatory filings or press mentions identify individuals with investment authority at the firm.
How does Break Off Capital source proprietary deal flow?
The firm discloses no information about its sourcing model, LP network, co-investor relationships, or origination channels. Without public portfolio companies or named team members, the sourcing mechanism cannot be verified from outside parties.
Is Break Off Capital structured as a single family office or a traditional venture firm?
Altss classifies Break Off Capital as an asset manager with a private equity subtype, not a single or multi-family office. The firm does not publicly clarify whether it manages third-party capital or proprietary family wealth, and no regulatory disclosures confirm its legal structure or client base.
Does Break Off Capital participate in fund commitments or only direct deals?
No information is available on whether Break Off Capital operates through direct investments, fund commitments, SPVs, or co-investment vehicles. The firm has published no details about its investment structures or tenure in any publicly traceable transaction.
What investment stages does Break Off Capital typically target?
The firm's self-description indicates a generalist venture strategy, but it does not specify stage preferences — such as pre-seed, seed, Series A, or growth. No portfolio companies are named that would allow stage-mapping from external data.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: